Kestra Q2 FY26 revenue $22.6M (+53% YoY); guides FY26 to $91M (+52% YoY)

KESTRA MEDICAL TECHNOLOGIES, LTD.

2025-Q2 EPS reported -$1.14 revenue$41,937,000

Gross margin expanded to 50.6% from 39.6% YoY, driven by volume leverage and a higher mix of in-network patients.
GAAP net loss $32.8M; adjusted EBITDA loss $19.7M vs $16.1M prior year.
Prescriptions for ASSURE system grew 54% YoY to 4,696; revenue benefited from market share gains and WCD market expansion.
Raised FY26 revenue guidance to $91M (52% growth); cash $175M at Oct 31 (excl. $148M net from subsequent equity offering).
CEO cites strong commercial momentum, positive post-approval study data, and balance sheet fortification.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.